Product Description
Mechanisms of Action: Histamine Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: New Zealand | Portugal | Spain | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 14-DK-0084 | P2 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2014-03-20 |
2020-06-10 |
Patient Enrollment|Primary Endpoints|Treatments |